What is Checkpoint Therapeutics Financial Strength?
Checkpoint Therapeutics has the Financial Strength Rank of 6.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
Checkpoint Therapeutics has no long-term debt (1).
As of today, Checkpoint Therapeutics's Altman Z-Score is -51.60.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Competitive Comparison of Checkpoint Therapeutics's Financial Strength
For the Biotechnology subindustry, Checkpoint Therapeutics's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Checkpoint Therapeutics's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Checkpoint Therapeutics's Financial Strength distribution charts can be found below:
* The bar in red indicates where Checkpoint Therapeutics's Financial Strength falls into.
Checkpoint Therapeutics Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Checkpoint Therapeutics's Interest Expense for the
months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the
months ended in Mar. 2024 was $-10.95 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil.
Checkpoint Therapeutics's Interest Coverage for the quarter that ended in Mar. 2024 is
| Checkpoint Therapeutics had no long-term debt (1). |
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Checkpoint Therapeutics Inc has no debt.
2. Debt to revenue ratio. The lower, the better.
Checkpoint Therapeutics's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Checkpoint Therapeutics has a Z-score of -51.60, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
Warning Sign:
Altman Z-score of -51.6 is in distress zone. This implies bankruptcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Checkpoint Therapeutics (Checkpoint Therapeutics) Business Description
Traded in Other Exchanges
Address
95 Sawyer Road, Suite 110, Waltham, MA, USA, 02453
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in us. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP).
Executives
| William Garrett Gray |
officer: See Remarks |
2 GANSEVOORT STREET,, 9TH FLOOR, NEW YORK NY 10014 |
| Oliviero James F Iii |
director, officer: CEO, President and Director |
C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022 |
| Fortress Biotech, Inc. |
10 percent owner |
1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS FL 33154 |
| Michael S Weiss |
director |
750 LEXINGTON AVE, NEW YORK NY 10022 |
| Neil Herskowitz |
director |
2109 BROADWAY, SUITE 206, NEW YORK NY 10023 |
| Christian Bechon |
director |
C/O LFB, 3, AVENUE DES TROPIQUES, LES ULIS, COURTABOEUF I0 91940 |
| Barry M Salzman |
director |
464 COMMON STREET, SUITE 301, BELMONT MA 02478 |
| Scott Boilen |
director |
2 SKYLINE DRIVE, HAWTHORNE NY 10532 |
| Rosenwald Lindsay A Md |
director |
375 PARK AVE, NEW YORK NY 10152 |
| David J Horin |
officer: Interim CFO |
1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CKPT has been successfully added to your